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Abstract
Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is
surgery. In 2016, an international meeting entitled “MPNST State of the Science: Outlining a Research Agenda for the Future”
was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of
standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging
guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the
transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic,
histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty
centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST tran-
sition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize avail-
ability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to
minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples,
data sharing should be incentivized.
Malignant peripheral nerve sheath tumor (MPNST) is an aggres-
sive soft tissue sarcoma associated with dismal clinical out-
comes. The risk of MPNST is dramatically increased in
individuals with neurofibromatosis type 1 (NF1). In 2002, an
international consensus meeting on NF1-associated MPNSTs (1)
emphasized the importance of a multidisciplinary approach,
molecular genetic studies to identify patients at high risk, devel-
opment of an international database and tumor bank, new
imaging methods, and the need for targeted therapies.
Although the clinical outcome for MPNST has not changed sub-
stantially in the past 15 years, there has been progress in our
understanding of the natural history, biology, and pathogenesis
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Commentary
of these cancers. These insights, combined with the availability
of next-generation sequencing technologies and preclinical
MPNST models, hold great promise to improve outcomes for
patients with or at risk for MPNST.
In 2016, a second international meeting titled “MPNST State
of the Science: Outlining a Research Agenda for the Future” was
convened to address how recent advances can be translated
into novel therapies and prevention strategies. In preparation
for this meeting, the state of MPNST research was reviewed (2).
The conference then divided into five working groups: diagno-
sis, imaging, and primary management; pathology; genomics
and biomarkers; preclinical models; and clinical trials method-
ology. Working group members (listed in the Supplementary
Materials, available online), were charged with developing
group-specific research priorities for the next five to 10 years.
The proposed priorities were then discussed and refined by the
participants in the entire conference. In addition, a keynote
speaker and invited panel of data science experts discussed
how data-intensive, novel problem-solving approaches (eg, a
“hackathon”) can be applied to MPNST. This report and Table 1
summarize the consensus of the individual working groups for
research priorities in NF1-associated MPNST.
Diagnosis, Imaging, and Primary Management
The group agreed that complete surgical resection with wide
negative margins is the optimum management of high-grade
MPNST and that early diagnosis and potential prevention of
MPNST should be prioritized.
Diagnosis
Heightened surveillance is required when risk factors for
MPNST are present. These include whole NF1 gene deletion,
family history of MPNST, prior radiation therapy, large plexi-
form neurofibroma burden or multiple distinct nodular lesions
on magnetic resonance imagining (MRI), neurofibromatous
neuropathy, and atypical neurofibroma(s). Painful, firm, and
rapidly-growing masses require investigation for potential
Table 1. Summary of Recommendations from “MPNST State of the Science: Outlining a Research Agenda for the Future” (October 2016 confer-
ence at the National Institutes of Health, Bethesda, MD)*
Topic Key research recommendations
Diagnosis, imaging, and
primary management
Development of:
1) standardized FDG-PET and MRI imaging guidelines;
2) cost-efficient whole-body MRI imaging protocols and prospective trials of their value in MPNST
detection;
3) prospective trials evaluating the role of chemotherapy and radiation potentially in combination with immuno-
therapy or other targeted agents on survival in MPNST.
Pathology Investigation of:
1) the histology and immunohistochemical features associated with transformation of plexiform neurofibroma to
MPNST;
2) the pathobiology, genetics, and histology of atypical neurofibromatous neoplasms of uncertain biologic poten-
tial (ANNUBP);
3) clinical behavior of ANNUBPs vs low-grade MPNSTs, ideally from patients with preoperative imaging and long-
term follow-up.
Genomics and
biomarkers
Development of:
1) a centralized database of comprehensive, standardized clinical data from MPNST subspecialty centers;
2) a mechanism for prospective MPNST and precuror sample collection from NF1 and sarcoma clinical trial
groups;
3) single-cell sequencing methodologies to define the extent and clinical significance of MPNST intratumoral
heterogeneity.
Preclinical models Development of:
1) a central repository of DNA-fingerprinted MPNST lines;
2) zebrafish MPNST models;
3) mouse models to study the plexiform neurofibroma to MPNST transition, MPNST metastasis, and drug
resistance;
4) patient-derived xenograft models.
Clinical trial
methodology
Development of:
1) historical controls using baseline time-to-progression data from completed studies to inform future MPNST
trials;
2) novel trials for patients with newly diagnosed and fully resectable MPNST;
3) novel trial designs that minimize regulatory requirements and maximize enrollment efficiency, eg, multiple-
arm studies of new agents or combination therapies.
MPNST “hackathon” Incentivization of the MPNST community to:
1) combine existing published and unpublished data;
2) develop a core set of questions that articulate the key problems in MPNST;
3) foster a collaborative research environment.
*ANNUBP ¼ atypical neurofibromatous neoplasms of uncertain biologic potential; FDG-PET ¼ fluorodeoxyglucose-positron emission tomography; MPNST ¼ malignant
peripheral nerve sheath tumor; MRI ¼magnetic resonance imaging; NF1 ¼ neurofibromatosis type 1.
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malignancy. MRI and fluorodeoxyglucose-positron emission
tomography (FDG-PET) imaging have a role in the diagnosis of
malignant transformation. Standardization of imaging proto-
cols is needed to define the diagnostic utility of both approaches
and to permit meaningful comparisons across institutions.
Whole-body MRI (WBMRI) is potentially useful to detect MPNST
and for surveillance after therapeutic intervention, but WBMRI
protocols are needed that are cost-efficient and covered by in-
surance carriers (imaging studies are billed based on number of
body parts imaged in many institutions).
It was concluded that a diagnostic biopsy is required for
masses concerning for high-grade MPNST to facilitate optimal
surgical planning. Ideally these biopsies should be performed or
directed by the team performing the surgery. Conversely, a
mass likely to be a low-grade/atypical neurofibroma may not re-
quire biopsy prior to resection because this would not affect sur-
gical management.
Management
There was consensus that precursors for MPNST (atypical
neurofibroma and low-grade MPNST) should be surgically
resected if they can be easily removed with low potential for
morbidity. Resection with wide margins is not necessary, and
preservation of neurological function is of paramount
importance.
The pathology working group removed the diagnosis of
“low-grade MPNST” because it cannot be differentiated from
atypical neurofibroma. Nonetheless, participants recommended
standardization of detailed pathology reports commenting on
cellularity, number of mitoses, and degree of atypia to facilitate
clinical correlation.
The management of deep-seated, concerning masses or of
multiple potential MPNSTs is challenging and should be guided
by pain, tumor growth, functional impairment, FDG avidity, MRI
characteristics, and interval change.
There was no consensus on the use of chemotherapy for
MPNST, and there are no prospective data on the effect of
chemotherapy on survival. Radiation oncologists and oncologic
surgeons agreed that radiation should be administered to large,
high-grade MPNST, ideally in the preoperative setting when
expected toxicity is lower and a smaller radiation field can be
used.
Research priorities identified by the group include the devel-
opment of 1) standardized FDG-PET and MRI imaging guidelines
for evaluation of masses concerning for MPNST; 2) prospective
studies analyzing the potential value of WBMRI in the detection
of MPNST, which could be combined with a detailed prospective
study of individuals at high risk for malignant transformation
of neurofibromas, including clinical manifestations, imaging,
and genomic characteristics of tumor samples correlated with
diagnostic and interventional modalities; 3) WBMRI cost-
efficient imaging protocols; and 4) prospective trials evaluating
the role of chemotherapy and radiation therapy, potentially in
combination with immunotherapy or other targeted therapy on
survival in MPNST.
Pathology
Pathologists can almost always classify cases of peripheral
nerve sheath tumors in NF1 patients as either benign or malig-
nant using histologic evaluation and immunohistochemical
studies. For those rare borderline or atypical masses that are
difficult to classify, there is a lack of evidence to support a unify-
ing standardized workup. With the overarching goal to avoid
overtreatment of nonmalignant peripheral nerve sheath tumors
(and undertreatment of malignant ones) in NF1 patients, the
pathology working group proposes guidelines to define subsets
of borderline lesions that will require validation.
Neurofibroma with cytologic atypia in the absence of
increased mitotic activity is a nonmalignant process. However,
neurofibromatous tumors containing various combinations of
high cellularity, nuclear atypia, and low mitotic activity of less
than 3/10 high-power fields (HPFs) are of uncertain biologic po-
tential. They overlap with tumors often designated, especially
in the past, as low-grade MPNSTs (3).
In contrast, MPNST is defined by high cellularity, nuclear
atypia, usually brisk mitotic activity (>10/10 HPFs), and often
tumor necrosis. Tumors with only some of these criteria and
lower mitotic rates may represent an intermediate category
that needs validation. Biomarkers that may prove helpful in
highlighting the transformation of a neurofibroma into an
MPNST include the following:
• Schwannian cell lineage markers S100/Sox10: often lost in
malignant transformation;
• CD34 fibroblastic framework: often lost in high-grade
MPNST;
• Ki67 greater than 10%: suggests malignancy;
• p16/CDKN2A loss: a step in transition from plexiform neuro-
fibroma to MPNST, occasionally observed in histologically
defined neurofibroma;
• H3K27me3: variably observed loss in MPNST;
• TP53: extensive positivity suggests high-grade MPNST.
To clarify the biologic potential of atypical neurofibromatous
neoplasms of uncertain biologic potential (ANNUBP), the path-
ology working group proposes a retrospective study of border-
line malignant nerve sheath tumors diagnosed either as
atypical neurofibromas/nerve sheath tumors or low-grade ma-
lignant MPNSTs. To improve the clinical correlation, the tumors
will be selected from patients with preoperative imaging and
long-term clinical follow-up. It is anticipated that the results of
this study will give better guidance to surgeons and other clini-
cians for optimal management of borderline malignant periph-
eral nerve sheath tumors in NF1. In some cases, a better
understanding of biologic potential may direct surgeons to
more appropriate resections with respect to surgical margins.
Genomics and Biomarkers
Participants in the Genomics and Biomarkers session considered
the results of other successful large-scale collaborative efforts
within the NF1 research community, such as the NF1 Optic
Pathway Glioma (NF1-OPG) Task Force, the Children’s Tumor
Foundation (CTF) Synodos NF1 Low-Grade Glioma (LGG)
Consortium, and the International NF1 Autism Collaborative
Team (INFACT) project (4). The NF1-OPG Task Force project built
upon single-site (5) and multi-institution clinical sample aggre-
gates (6,7) to establish that female sex and glioma brain location
are important predictors of clinical outcome. Similarly, the power
of the INFACT study, which included existing data from over 530
subjects from six clinical centers worldwide, was the ability to
undercover important features of NF1-related autism not pos-
sible when smaller individual site cohorts were employed.
Modeled on these successes, similar adequately powered
efforts may reveal previously unrecognized, but clinically
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useful, prognostic clues about MPNST natural history and
biology. The participants in this session proposed three research
priorities. First, to determine the natural history and phenotypes
of NF1-associated MPNST and precursor lesions (eg, atypical or
nodular plexiform neurofibromas), a centralized database
should be established. The goal would be to collect, in a standar-
dized manner, histologic, immunohistochemical, molecular,
radiographic, treatment, and related clinical data from centers
worldwide with expertise in these NF1-related cancers.
Although retrospective in nature, the resulting data from this
registry may reveal previously unanticipated patterns, similar to
the INFACT effort outcome. This registry would then allow the
acquisition of MPNST (and precursor) biospecimens (frozen or
paraffin-embedded), germline (or normal tissue DNA) samples,
and any previously somatic whole-exome or whole-genome
sequencing data for aggregate analyses. All data would be de-
identified and shared in accordance with local institutional re-
view board requirements. Regular follow-up, transparency, and
accountability will be hallmarks of this effort. As of October 2016,
116 individuals with a diagnosis of MPNST have been entered
into the CTF NF registry (www.nfregistry.org).
The second priority is to develop a mechanism for prospect-
ive MPNST sample collection. This will require coordination be-
tween NF1 and sarcoma clinical trial groups to maximize the
capture of pathologic materials, as well as to develop uniform
standard operating procedures for consent, biospecimen collec-
tion and processing, pathology review, and nucleotide extrac-
tion. A similar standardized approach was recommended to
facilitate the collection of serum and/or plasma samples for bio-
marker studies. For sample tracking and storage, the biobank
could either be a physical, centralized entity (eg, the CTF bio-
bank) or a decentralized, virtual one (eg, a catalog of available
samples at different institutions). Consideration should also be
given to the use of “crowdsourcing” (eg, social media) as a re-
cruitment tool.
The third priority is the use of single-cell sequencing meth-
odologies to define the extent and clinical significance of
MPNST intratumoral heterogeneity. Multiple analytic platforms,
including those that employ DNA, RNA, methylation (epigenet-
ics), and microRNA analyses, are needed. In this manner, the
identification of clonal variation within these malignancies
may yield important insights into the evolution of metastasis
and the mechanisms that underlie therapeutic resistance.
Preclinical Models
Since the last consensus meeting, robust models of MPNST
have been developed, and their advantages and disadvantages
in discovery and translational research were discussed.
Opportunities for discovery research in MPNST that were dis-
cussed included identification of MPNST-specific cell surface
proteins, circulating antigens and DNA for liquid biopsies, and
drug resistance mechanisms.
Translational studies for MPNST are either performed in
xenografts of human cell lines into immunocompromised mice,
in patient-derived xenograft (PDX) models, or in genetically
engineered animal models (2). To avoid misidentification of
MPNST cell lines due to lapses in quality control and documen-
tation, the group recommended DNA fingerprinting and depos-
ition of MPNST lines in a central repository. PDX models (2) may
be more predictive than cell line xenografts of patient responses
to treatment, although this requires more rigorous testing. PDX
models of MPNSTs have been challenging to generate but now
exist (8), and they should be characterized and made available
through a central repository to ensure quality control.
Nf1-mutant models in yeast (IRA1/2) (9), fly (10), slime mold
(11), and zebrafish (12) have been reported. Zebrafish Nf1
mutants develop fish MPNST when crossed to other mutations
and may be useful for preclinical drug screening (13).
Participants supported further development of zebrafish
MPNST models and incentivizing collaborations between NF1
and zebrafish research communities. Genetically engineered
mouse models (GEMMs) (2) harboring mutations in Nf1 and
Trp53 develop MPNSTs with concomitant changes in the micro-
environment and are currently being routinely used in preclin-
ical drug testing. At least nine Nf1-mutant MPNST GEMMs have
been reported in the literature to date, with differences in grade,
latency, and penetrance (2). An updated pathology review of
MPNST GEMMs is needed to compare models with patient
MPNSTs. Although robust plexiform neurofibroma (PNF) models
exist, the PNF-to-MPNST transition has not yet been modeled in
GEMMs. A model of this transition would facilitate studies of
tumor progression mechanisms and would be useful for pre-
clinical testing of MPNST prevention. Validated models of
MPNST metastasis are also needed.
We recommend that preclinical drug testing for MPNST con-
tinue to use a “funnel” approach. Candidate drugs (or combina-
tions) should be screened in cultured MPNST cells, or model
organisms with short generation times, and studied for
cell-based mechanisms of action, such as cytostasis and/or
cytotoxicity. Promising candidates should be screened in
“medium-throughput” (zebrafish or mouse) vertebrate platforms
for general toxicity, tumor drug delivery, and in vivo effects on
tumor cells. Finally, top candidates should be tested in a GEMM
model: ideally, a mammalian system with an imprinted genome,
intact immune system, and co-evolution of the stroma and tumor.
The group recommends three ways to improve the use of
mouse models in preclinical trials. First, response criteria in
mice should be set as rigorously as in clinical trials, including
determining pharmacodynamics and pharmacokinetics of can-
didate drugs. Second, tumors need to be well established (at
least 150 mm3) to begin treatment trials, and researchers should
examine the durability of response and recurrence (if any) of
tumor growth after discontinuing therapy. Lastly, experimental
results using these rigorous criteria should guide moving candi-
date drugs into clinical trials.
Clinical Trials Methodology
The challenges in the clinical development of effective treat-
ments in MPNST include optimizing end points to increase the
accuracy and efficiency of clinical trials, assimilation of end
points across preclinical and clinical trials, specific study designs
for the various stages of MPNST evolution, and increasing the ef-
ficiency of opening and completing clinical trials in this ultrarare
disease. Participants of the clinical trials methodology working
group prioritized and addressed these challenges.
Optimized end points permit more accurate and efficient
clinical trials. To date, clinical trials in MPNST (14–19) have used
imaging end points with MRI or CT using WHO (20), RECIST (21),
or CHOI criteria (22). Functional imaging, such as FDG-PET and
magnetic resonance imaging apparent diffusion coefficient
(MRI ADC), and patient-reported outcomes, such as pain, should
be considered secondary end points to evaluate whether these
modalities can be incorporated as part of outcome measure-
ments. To date, clinical trials with noncytotoxic, targeted
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therapies for unresectable/recurrent MPNST have yet to demon-
strate an objective response using the traditional measures
noted above. The clinical benefit rate (CBR) has been recently
proposed as an end point. CBR is the sum of objective responses
and prolonged stable disease. Multiple negative phase II studies
for MPNST have been published or completed. Although disap-
pointing, there is a great opportunity to compile and analyze
the completed studies to develop a baseline time to progression
that can be used as a high-quality, relevant historical compari-
son for future MPNST phase II trials targeting recurrent disease.
The focus of most clinical trials in MPNST has been in the
setting of recurrent or unresectable disease. Finding therapies
for this group of patients with no known curative treatments is
a priority, and knowledge gained would translate to all MPNST
patients. However, the cohort of patients with newly diagnosed
and fully resectable MPNST has historically not been well
studied; from this group, we can potentially learn to effectively
treat and thus prevent recurrent disease. An additional consid-
eration for trials in people with newly diagnosed MPNST is that
this would more faithfully represent the preclinical study
designs, possibly allowing for more direct clinical translation.
For low-grade MPNST and atypical neurofibromatous neo-
plasms of uncertain biologic potential where surgery is planned
and there is no indication for neoadjuvant radiotherapy or chemo-
therapy, phase 0 trials can be utilized for proof of concept of target
inhibition and biomarker development. For newly diagnosed
patients recommended to have neoadjuvant chemotherapy, com-
bination studies with “standard” chemotherapy, such as doxorubi-
cin and ifosfamide with novel agents compared with historical
control from the SARC006 study (23), could also be developed.
Finally, experience from prior cooperative group MPNST stud-
ies has shown that the time to open one clinical trial can be up-
wards of two years, in part because of costs and regulatory
requirements. However, even for an ultrarare disease, accrual into
MPNST trials is rapid once a study opens. Hence there is motiv-
ation for trial designs that minimize regulatory requirements and
maximize availability to patients. The CTF and Neurofibromatosis
Therapeutic Acceleration Program (NTAP) sponsors the preclinical
NF consortium. This NF preclinical platform conducts preclinical
drug trials to identify agents for further study in clinical trials and
has been very productive (115 preclinical trials to date), delivering
several viable agents (16 drugs) to the clinical pipeline, including
the highly successful MEK inhibitors. Multiple-arm studies of new
agents (or combinations of agents), each guided by preclinical
data, should open in parallel or sequentially, with outcome com-
pared with historical controls. Such novel designs and forward
thinking are needed to move this field forward, and ultimately
find more effective treatment for MPNST.
Creating Greater Research Synergy: The
Potential of a “Hackathon” to Solve Critical
Problems in MPNST
Dr. Shasha Jumbe of the Gates Foundation served as the key-
note speaker and invited the group to consider a “hackathon” to
catalyze data science innovation and analyze increasingly plen-
tiful genomic data and to generate new hypotheses for future
research. In a “hackathon” or “data jam,” data scientists and
coders (the “crowd”) are invited to apply novel data exploration
and data analysis methods on curated and harmonized open
source data to solve complex problems in a sprint-like event.
Recent successful examples include a crowdsourced prostate
cancer prediction tool (http://sagebase.org/in-the-news/pros
tate-cancer-challenge-crowdsourcing-a-better-prostate-cancer-
prediction-tool/) and a contest to improve breast cancer detec-
tion through deep machine learning (https://www.synapse.org/
Digital_Mammography_DREAM_Challenge).
In 2014, to capitalize on available genomics data, the CTF
entered into a partnership with Sage Bionetworks to launch the
first ever NF data hub. Participants of all CTF-sponsored team
science programs (Synodos) are required to deposit their raw
data with Sage BioNetworks. The scientists at Sage have built
the platforms and analysis tools and integrated the cross-
disciplinary data sets in collaboration with the Synodos team
members. Additionally, other funders such as the National
Cancer Institute and NTAP deposit their data into this data hub.
To maximize the use of MPNST-associated data in a future
hackathon, the MPNST community should continue to share
and combine existing data (including published and unpub-
lished variables) and assess if they are of sufficient quality and
quantity. The community should develop a core set of questions
that articulate the key problems in MPNST. Initial query-driven
analyses on available data should direct which data gaps to fill,
and funders will be invited to formulate a strategy to enrich the
data set. Importantly, not all valuable questions lend them-
selves to hackathon sessions. Lastly, to be successful, a collab-
orative research environment needs to be created that fosters
success and incentivizes data sharing. This requires attention
to issues of authorship, attribution and ownership, funding,
availability of appropriate analytic and visualization tools, com-
mon data infrastructure and storage, and harmonization meth-
ods for data and metadata. Taken together, the NF1-MPNST
community is currently uniquely positioned to establish such a
consortium with a high likelihood of transforming the care of
individuals with these deadly cancers.
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